Gossamer Bio

Late-stage clinical biopharma, PAH/PH-ILD

GOSS · Nasdaq · United States

Share price · GOSS

$11.43-0.02 (-0.16%) 3M

close as of 2026-11-18 · 24h delayed · vol 243K (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GOSS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 27 Jul 2026+46.6%
  2. 18 May 2026-43.3%
  3. 23 Feb 2026-80.1%
  4. 6 Feb 2026-7.2%

    Nothing announced by GOSS that day or the session before.

  5. 23 Dec 2025-12.9%

    Nothing announced by GOSS that day or the session before.

  6. 3 Dec 2025+14.4%

    Nothing announced by GOSS that day or the session before.

Share of unusual movement by asset

For each asset, the share of GOSS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Seralutinib
events and moves
7shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—43%
Sessions with no dated event—54%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
PDGFR/CSF1R/KIT (multi-kinase)Small molecule
Pulmonary Arterial Hypertension

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
SeralutinibPhase 3Pulmonary Arterial Hypertension
Est. primary completion 2026-12 · NCT06274801 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 September 2026Filing submittedseralutinibSeralutinib NDA submitted to FDA for PAH
US, FDA · Gossamer Bio · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$38M$19M$51M+ $0 short-term inv.$48M-$30M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$9.2M$26M$41M+ $16M short-term inv.—-$39M operating cash flowreport ↗
2026-Q1$17M$43M$41M+ $58M short-term inv.$47M-$39M operating cash flowreport ↗
2025-Q3$13M$46M$8.9M+ $171M short-term inv.$48M-$36M operating cash flowreport ↗
2025-Q2$11M$42M$26M+ $187M short-term inv.$38M-$47M operating cash flowreport ↗
2025-Q1$9.9M$38M$29M+ $229M short-term inv.$37M-$40M operating cash flowreport ↗
2024-Q3$9.5M$35M$28M+ $299M short-term inv.$31M-$32M operating cash flowreport ↗
2024-Q2$96M$35M$87M+ $268M short-term inv.—$116M operating cash flowreport ↗
2024-Q1$0$32M$39M+ $206M short-term inv.$42M-$52M operating cash flowreport ↗
2023-Q3$0$31M$83M+ $246M short-term inv.$40M-$34M operating cash flowreport ↗
2023-Q2$0$36M$37M+ $125M short-term inv.$43M-$38M operating cash flowreport ↗
2023-Q1—$38M$65M+ $137M short-term inv.$49M-$53M operating cash flowreport ↗
2022-Q3—$45M$153M+ $151M short-term inv.$59M-$37M operating cash flowreport ↗
2022-Q2—$43M$94M+ $128M short-term inv.$56M-$49M operating cash flowreport ↗
2022-Q1—$42M$139M+ $133M short-term inv.$58M-$53M operating cash flowreport ↗
2021-Q3—$43M$214M+ $153M short-term inv.$60M-$42M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$48M$174M$38M+ $99M short-term inv.$43M-$171M operating cash flowreport ↗

For fiscal year 2025, Gossamer Bio reported revenue of $48.47M, down 57.7% YoY, with R&D spend of $174.09M, up 25.7% YoY. Cash and equivalents stood at $37.73M, and the company recorded a net loss of $170.37M, with a quarterly net burn of $170.37M.

Operationally, Gossamer is focused on advancing seralutinib for pulmonary hypertension and reported Phase 3 PROSERA topline results showing a placebo-adjusted 6MWD improvement of 13.3 meters at Week 24 (p=0.0320), which missed the prespecified alpha threshold of 0.025. The company plans to engage the FDA, including via a Type C meeting, to define a potential regulatory path forward, and has paused enrollment in the SERANATA Phase 3 study in PH-ILD while ongoing open-label extension studies continue. The report also notes the Chiesi collaboration for seralutinib and an option agreement with Respira for RT234, but provides no financial guidance.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$115M$138M$46M+ $248M short-term inv.$14M-$3.5M operating cash flowreport ↗
2023-FY$0$135M$32M+ $264M short-term inv.$45M-$159M operating cash flowreport ↗
2022-FY$0$171M$112M+ $144M short-term inv.$57M-$187M operating cash flowreport ↗
2021-FY—$170M$183M+ $142M short-term inv.$59M-$189M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-23Nathan Steven D · directorAward / grant (derivative)10,000——Form 4
2026-09-23Cox Russell J. · directorAward / grant (derivative)10,000——Form 4
2026-09-23Quisel John D · directorAward / grant (derivative)10,000——Form 4
2026-09-23Drynan Skye · directorAward / grant (derivative)10,000——Form 4
2026-09-23Ciongoli Gregory Austin · directorAward / grant (derivative)30,000——Form 4
2026-09-23Daniel Thomas O · directorAward / grant (derivative)10,000——Form 4
2026-09-23Milligan Sandra · directorAward / grant (derivative)10,000——Form 4
2026-08-24Hasnain Faheem · director, President & CEOAward / grant (derivative)166$1000.00$166KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 182 reporting institutions held 177.2M shares ($55.8M, 36.3% of shares outstanding).

#InstitutionSharesValue
1Kalehua Capital Management LLC17,708,133$5.8M
2BlackRock, Inc.16,826,695$5.5M
3AQR CAPITAL MANAGEMENT LLC10,126,897$3.3M
4VANGUARD CAPITAL MANAGEMENT LLC9,394,593$3.1M
5ARCH Venture Management, LLC8,055,916$2.6M
6Octagon Capital Advisors LP7,750,000$2.5M
7SAMSARA BIOCAPITAL, LLC7,222,559$2.4M
8Balyasny Asset Management L.P.5,922,298$1.9M
9Siren, L.L.C.5,208,968$1.7M
10683 Capital Management, LLC5,000,000$1.6M
11HHLR ADVISORS, LTD.4,974,041$1.6M
12GEODE CAPITAL MANAGEMENT, LLC4,939,691$1.6M
13Qube Research & Technologies Ltd4,917,763$1.6M
14TWO SIGMA INVESTMENTS, LP4,780,851$1.6M
15STATE STREET CORP4,388,109$1.4M